Tacrine (TC) (9-amino-1,2,3,4-tetrahydroacridine), a non-selective, reversible cholinesterase inhibitor, affecting acetylcholinesterase and butyrylcholinesterase, was launched as the first drug to alleviate the symptoms of Alzheimer’s disease (Crismon, 1994). This evidence concerns the gene BCHE and early-onset autosomal dominant Alzheimer disease.